首頁 > 市場調查報告書 > 製藥

生物製劑

免疫學市場規模、佔有率和成長分析（按分銷管道、疾病和地區分類）—產業預測（2026-2033 年）

市場調查報告書

商品編碼

1899822

免疫學市場規模、佔有率和成長分析（按分銷管道、疾病和地區分類）—產業預測（2026-2033 年）

Immunology Market Size, Share, and Growth Analysis, By Distribution Channel (Hospital Pharmacies, Online Pharmacies), By Disease Indication (Rheumatoid Arthritis, Psoriatic Arthritis), By Region -Industry Forecast 2026-2033

出版日期: 2025年12月19日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，免疫學市場規模將達到 1,042 億美元，到 2025 年將達到 1,168.1 億美元，到 2033 年將達到 2912.9 億美元，預測期（2026-2033 年）的複合年成長率為 12.1%。

免疫學市場正經歷強勁成長，這主要得益於對包括硬化症、類風濕性關節炎和發炎性腸道疾病在內的各種免疫介導疾病治療方法需求的不斷成長。該領域涵蓋了廣泛的藥物、治療方法、診斷試劑和研究設備，旨在識別、控制或預防過敏、癌症、自體免疫疾病和感染疾病等疾病。先進的生物技術對於開發旨在調節免疫系統功能的標靶治療至關重要。該市場的主要組成部分包括疫苗、免疫調節劑和單株抗體。酵素連結免疫吸附ELISA檢驗)、流式細胞技術和基於聚合酶鍊式反應 (PCR) 的技術等診斷工具在評估免疫系統功能和檢測各種免疫標記方面發揮重要作用。此外，免疫療法已成為一種重要的癌症治療方法，這激發了人們對發現新的治療標靶的研發興趣。

免疫學市場促進因素

全球免疫學市場的主要促進因素之一是自體免疫疾病和慢性發炎性疾病的日益普遍。全球人口老化和生活方式的改變導致類風濕性關節炎、狼瘡和發炎性腸道疾病等疾病顯著增加。不斷擴大的患者群體需要創新的免疫療法和生物製藥，從而推動了研發投入。此外，人們對免疫系統功能的認知不斷提高，以及精準醫療和個人化醫療保健的進步，正在推動治療方法的改進，從而維持免疫學領域的強勁成長，並改善全球患者的治療效果。

免疫學市場限制因素

全球免疫學市場面臨的主要限制因素之一是免疫療法研發和生產高成本。這些先進治療方法通常需要大量的研發投入和嚴格的監管核准，這可能會限制患者的可及性和負擔能力。此外，免疫相關疾病的複雜性需要專業的知識和基礎設施，這為中小企業進入市場設置了障礙。另外，潛在的副作用和患者反應的個體差異也會阻礙免疫療法的廣泛應用，並使醫療服務提供者和支付方對支持創新免疫療法持謹慎態度。

免疫學市場趨勢

精準醫療的興起正在重塑免疫學市場，其推動的個人化治療策略是根據每個人的基因和分子特徵量身定做的。這種轉變提高了治療效果，同時最大限度地減少了副作用，從而提高了醫療專業人員和患者的接受度。基因組學、蛋白質組學和生物標記監測等領域的持續進步，為創新標靶治療鋪平了道路，並推動了對更專業化治療方法的需求。這一發展與以患者為中心的醫療保健模式的更廣泛轉變完美契合，凸顯了滿足每位患者獨特需求的個人化醫療保健方法的重要性，最終引領免疫學領域走向更加個性化的未來。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲（MEA）
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭格局

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市集活動
主要企業市佔率（2025 年）

主要企業簡介

AbbVie, Inc.（US）
Janssen Global Services, LLC（US）
Eli Lilly and Company（US）
Novartis AG（Switzerland）
Pfizer Inc.（US）
Bristol-Myers Squibb Company（US）
Merck Sharp & Dohme Corp.（US）
F. Hoffmann-La Roche Ltd.（Switzerland）
Amgen Inc.（US）
Astellas Pharma Inc.（Japan）
UCB SA（Belgium）
Sanofi（France）
Gilead Sciences, Inc.（US）
Regeneron Pharmaceuticals, Inc.（US）
Teva Pharmaceutical Industries Ltd.（Israel）
Takeda Pharmaceutical Company Limited（Japan）
Horizon Therapeutics plc（Ireland）
Aimmune Therapeutics, Inc.（US）
Celgene Corporation（US）
Incyte Corporation（US）
Boehringer Ingelheim GmbH（Germany）
Abbott Laboratories（US）

簡介目錄

Product Code: SQMIG35H2245

Immunology Market size was valued at USD 104.2 Billion in 2024 and is poised to grow from USD 116.81 Billion in 2025 to USD 291.29 Billion by 2033, growing at a CAGR of 12.1% during the forecast period (2026-2033).

The immunology market is experiencing robust growth, propelled by the rising demand for therapies addressing various immune-mediated disorders, including sclerosis, rheumatoid arthritis, and inflammatory bowel disease. This sector encompasses a broad spectrum of medications, treatments, diagnostics, and research instruments aimed at identifying, managing, or preventing conditions such as allergies, cancer, autoimmune diseases, and infections. Advanced biotechnological techniques are pivotal in developing targeted treatments that modify immune system functions. Key components in this market include vaccines, immunomodulators, and monoclonal antibodies. Diagnostic tools, such as ELISA assays, flow cytometry, and PCR-based methods, play a vital role in assessing immune system performance and detecting various immunological markers. Additionally, immunotherapy has emerged as a significant cancer treatment, heightening interest in research aimed at uncovering novel therapeutic targets.

Top-down and bottom-up approaches were used to estimate and validate the size of the Immunology market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Immunology Market Segments Analysis

Global Immunology Market is segmented by Drug Class, Disease Indication, Distribution Channel, and region. Based on Drug Class, the market is segmented into Monoclonal Antibody, Immunosuppressants, Fusion Proteins, Others. Based on Disease Indication, the market is segmented into Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, Ankylosing Spondylitis, Inflammatory Bowel Disease, Prophylaxis of Organ Rejection, and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Immunology Market

One of the key market drivers for the Global Immunology Market is the increasing prevalence of autoimmune diseases and chronic inflammatory disorders. As the global population ages and lifestyles evolve, there is a noticeable rise in conditions such as rheumatoid arthritis, lupus, and inflammatory bowel disease. This growing patient demographic necessitates innovative immunological therapies and biologics, propelling research and development efforts. Furthermore, heightened awareness of immune system functions, along with advancements in precision medicine and personalized healthcare, are fostering improved treatment options, thus sustaining robust growth in the immunology sector and enhancing patient outcomes worldwide.

Restraints in the Immunology Market

One key market restraint for the global immunology market is the high cost associated with the development and manufacturing of immunological therapies. These advanced treatments often require significant investment in research and development, as well as stringent regulatory approvals, which can limit accessibility and affordability for patients. Additionally, the complex nature of immune-related diseases necessitates specialized expertise and infrastructure, creating barriers for smaller companies to enter the market. This, combined with the potential for adverse effects and the variability in individual patient responses, hampers broader adoption and can lead to hesitance among healthcare providers and payers in supporting innovative immunotherapy solutions.

Market Trends of the Immunology Market

The advent of precision medicine is reshaping the immunology market by fostering personalized treatment strategies tailored to individual genetic and molecular profiles. This transformation enhances therapeutic efficacy while minimizing adverse effects, contributing to its rising acceptance among healthcare professionals and patients alike. Continuous advancements in fields such as genomics, proteomics, and biomarker research are paving the way for innovative targeted therapies, driving demand for more specialized treatments. This evolution aligns seamlessly with the broader shift toward patient-centered care models, emphasizing the importance of individualized approaches in healthcare that cater to the unique needs of each patient, ultimately steering the immunology landscape towards a more tailored future.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Value Chain Analysis
Ecosystem of the Market
Case study Analysis
Regulatory Landscape
Innovation Matrix
Top Investment Analysis
Key Success Factor
Degree of Competition

Immunology Market by Drug Class

Market Overview
Monoclonal Antibody
Immunosuppressants
Fusion Proteins
Others

Immunology Market by Disease Indication

Market Overview
Rheumatoid Arthritis
Psoriatic Arthritis
Plaque Psoriasis
Ankylosing Spondylitis
Inflammatory Bowel Disease
Prophylaxis of Organ Rejection
Others

Immunology Market by Distribution Channel

Market Overview
Offline Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
Online Channel

Immunology Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2025

Key Company Profiles

AbbVie, Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Janssen Global Services, LLC (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck Sharp & Dohme Corp. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Astellas Pharma Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
UCB SA (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regeneron Pharmaceuticals, Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Horizon Therapeutics plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aimmune Therapeutics, Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Celgene Corporation (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Incyte Corporation (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments